Salford’s Community Based Movement Disorder Service: Providing integrated care for people in their own homes.
Objective: Our service aims to provide integrated care for older people living with movement disorders.We review our patients in the own home and coordinate their…Lumbar Punctures in Parkinson’s Research
Objective: This study aims to explore patient perspectives on lumbar punctures for cerebrospinal fluid (CSF) analysis in Parkinson’s disease (PD) research, with the objective of…The bypassing and embedded PEG J
Objective: Our aim is to highlight the improvement on quality of life of using a duodenal levodopa infusion. In addition, we want to emphasize the continuing…Preliminary Efficacy of Bilateral Intraputaminal Delivery of GDNF Gene Therapy (AAV2-GDNF; AB-1005) in Parkinson’s Disease: 18-Month Follow-Up From a Phase 1b Study
Objective: To assess the preliminary efficacy of bilateral intraputaminal delivery of adeno-associated virus serotype 2 containing glial cell line–derived neurotrophic factor (AAV2-GDNF; AB-1005) for patients…Motor Impact of Fasting in Parkinson’s Disease Patients: An overview
Objective: To provide a literature overview of fasting impact on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…Analgesic effect of electroacupuncture on Relieving pain in Parkinson’s disease and the mechanism based on rs-fMRI
Objective: To investigate whether electroacupuncture (EA) on the primary motor cortex could reduce pain in patients with PD and to explore the mechanism behind its…Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
Objective: Evaluate the pharmacokinetics (PK), safety, and tolerability of a once-daily (QD) suvecaltamide (JZP385) formulation and its major active metabolites (JZZ05000034=M01, JZZ05000035=M02) in a Phase…Sympathetic Nervous System Overactivity in the Pre-Motor Stage of Parkinson’s Disease: Therapeutic Implications
Objective: To investigate sympathetic nervous system (SNS) activity in idiopathic REM behavior disorder (iRBD) subjects at risk for Parkinson's disease (PD), and the effect of…Unmet Motor and Nonmotor Needs of People with Parkinson’s in the Final Year of Life
Objective: To assess main issues People with Parkinson’s (PD, PwP) wished to discuss at clinical consultations with movement disorders specialists during the final year of…
- « Previous Page
- 1
- …
- 317
- 318
- 319
- 320
- 321
- …
- 1734
- Next Page »